Resistance surveillance program report for selected European nations (2011)

Diagnostic Microbiology and Infectious Disease

Volumn 78, Issue 4, 2014, Pages 429-436

  Jones, Ronald N ^a   Flonta, Mirela ^b   Gurler, Nazahat ^c   Cepparulo, Mario ^d   Mendes, Rodrigo E ^a   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b Infectious Diseases Hospital   (Romania)

^c ISTANBUL UNIVERSITY   (Turkey)

^d PFIZER INC   (United States)

Author keywords

2011; Europe; Resistance; Surveillance

Indexed keywords

AMIKACIN; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; COLISTIN; COTRIFAMOLE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BELGIUM; BIOSURVEILLANCE; BULGARIA; CONTROLLED STUDY; CROATIA; CZECH REPUBLIC; ESCHERICHIA COLI; FRANCE; GERMANY; GREECE; IRELAND; ISRAEL; ITALY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; POLAND; PORTUGAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ROMANIA; RUSSIAN FEDERATION; SLOVAKIA; SLOVENIA; SPAIN; STAPHYLOCOCCUS SIMULANS; SWEDEN; TURKEY (REPUBLIC); UKRAINE; UNITED KINGDOM; VANCOMYCIN RESISTANT ENTEROCOCCUS;

2011; EUROPE; RESISTANCE; SURVEILLANCE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84895860981     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.10.008     Document Type: Article

References (24)

1. Bolmstrom A., Ballow C.H., Qwarnstrom A., Biedenbach D.J., Jones R.N. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin Microbiol Infect 2002, 8:791-800.
2. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004, 48:1-14.
3. Canton R., Akova M., Carmeli Y., Giske C.G., Glupczynski Y., Gniadkowski M., et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012, 18:413-431.
4. Castanheira M., Sader H.S., Deshpande L.M., Fritsche T.R., Jones R.N. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52:570-573.
5. Castanheira M., Mendes R.E., Woosley L.N., Jones R.N. Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY Antimicrobial Surveillance Programme (2007-09). J Antimicrob Chemother 2011, 66:1409-1411.
6. Castanheira M, Deshpande LM, Hryniewicz W, Stefaniuk E, Goossens H, Jones RN. Characterization of three new VIM enzymes, VIM-35, VIM-36 and VIM-37 identified in European countries: report of the SENTRY Antimicrobial Surveillance Programme. In 23rd ECCMID, April 27-30, 2013. Abstr. #P1283. Berlin, Germany. 2013.
7. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition, M07-A9. Wayne, PA: CLSI; 2012.
8. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 23rd informational supplement M100-S23. Wayne, PA: CLSI; 2013.
9. Cornaglia G., Giamarellou H., Rossolini G.M. Metallo-beta-lactamases: a last frontier for beta-lactams?. Lancet infect Dis 2011, 11:381-393.
10. Diaz L., Kiratisin P., Mendes R., Panesso D., Singh K.V., Arias C.A. Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis. Antimicrob Agents Chemother 2012, 56:3917-3922.
11. EARS-Net Antimicrobial Resistance Surveillance in Europe Available at, Accessed June 2013. http://ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/epidemiological_data/Pages/ears-net_annual_reports.aspx.
12. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0, January 2013. Available at. Accessed January 2, 2013. http://www.eucast.org/clinical_breakpoints/.
13. Flamm R.K., Mendes R.E., Ross J.E., Sader H.S., Jones R.N. An international activity and spectrum analysis of linezolid: ZAAPS program results for 2011. Diagn Microbiol Infect Dis 2013, 76:206-213.
14. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
15. Mendes R.E., Deshpande L.M., Farrell D.J., Spanu T., Fadda G., Jones R.N. Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy. J Antimicrob Chemother 2010, 65:2329-2335.
16. Papp-Wallace K.M., Endimiani A., Taracila M.A., Bonomo R.A. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011, 55:4943-4960.
17. Rice L.B. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc 2012, 87:198-208.
18. Rodloff A.C., Leclercq R., Debbia E.A., Canton R., Oppenheim B.A., Dowzicky M.J. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin Microbiol Infect 2008, 14:307-314.
19. Rolain J.M., Parola P., Cornaglia G. New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?. Clin Microbiol Infect 2010, 16:1699-1701.
20. Sader H.S., Farrell D.J., Jones R.N. Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. Int J Antimicrob Agents 2010, 36:28-32.
21. Sader H.S., Farrell D.J., Jones R.N. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7years of resistance surveillance (2003-2009). J Chemother 2011, 23:200-206.
22. Shlaes D.M. New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci 2013, 1277:105-114.
23. Tygacil® Package Insert 2012. Wyeth Pharmaceuticals, Philadelphia, PA. Available at www.tygacil.com. Accessed January 2013.
24. Woodford N., Livermore D.M. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009, 59(Suppl. 1):S4-S16.